AMGN
AMGEN INC
Nasdaq: AMGN · Thousand Oaks, CA · Healthcare
$344.86-5.30 (-1.51%)Closed
Market Cap$185.81B
Cash$9.13Bmost recent
Runwayprofitable
P/E (TTM)24.2EPS $14.23
52-Wk Range$254.30 – $388.16
Avg Volume2.6M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$344.86+34.8%
Pipeline

Drug candidates sponsored by AMGEN · ClinicalTrials.gov

65 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Sensipar®
Secondary Hyperparathyroidism
Completed
2006-10past
1
Phase 4cinacalcet
End Stage Renal Disease+2 more
Completed
2012-04-10past
2
Phase 4Peginesatide
Anemia
Terminated
2013-03past
1
Phase 4Darbepoetin alfa
Chronic Kidney Disease+12 more
Completed
2014-03-03past
6
Phase 4800 mg ibuprofen/26.6 mg famotidine
Juvenile Idiopathic Arthritis
Completed
2015-03past
1
Phase 4Aranesp®
Chronic Renal Failure+1 more
Completed—1
Phase 3De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease+1 more
Completed
2005-03past
1
Phase 3Etanercept
Psoriasis+1 more
Completed
2008-12past
3
Phase 3Panitumumab
Metastatic Colorectal Cancer+5 more
Completed
2012-03-30past
3
Phase 3HPN-100
Urea Cycle Disorders+2 more
Completed
2013-02past
2
Phase 3Cetuximab
Metastatic Colorectal Cancer
Completed
2013-02-05past
1
Phase 3denosumab
Low Bone Mineral Density+5 more
Completed
2013-09past
3
Phase 3Placebo
Thrombocytopenia+7 more
Completed
2014-08past
6
Phase 3Romozosumab
Postmenopausal Osteoporosis
Completed
2015-05-14past
1
Phase 3Rilotumumab
Gastric Cancer+3 more
Completed
2015-06past
2
Phase 3Romosozumab
Postmenopausal Osteoporosis
Completed
2015-12-14past
1
Phase 3Evolocumab
Dyslipidemia+1 more
Completed
2016-11-11past
2
Phase 3Avacopan
ANCA-Associated Vasculitis
Completed
2019-09-07past
1
Phase 3Ivabradine
Heart Transplantation, Elevated Resting Heart Rate
Withdrawn
2020-02-19past
1
Phase 2Blinatumomab
B-Cell Non Hodgkin Lymphoma+1 more
Completed
2020-03-12past
2
Phase 3Teprotumumab
Thyroid Eye Disease
Completed
2020-06-08past
1
Phase 3Bemarituzumab
Gastric Cancer+1 more
Active, not recruiting
2025-10-14past
2
Phase 3Maridebart cafraglutide
Obstructive Sleep Apnea+3 more
Recruiting
2026-05-28
3
Phase 3Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Recruiting
2027-01-15
1
Phase 3Etelcalcetide
Hyperparathyroidism, Secondary+1 more
Recruiting
2027-06-30
2
Phase 3ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Active, not recruiting
2028-02-14
1
Phase 3apremilast
Plaque Psoriasis+5 more
Recruiting
2028-03-21
4
Phase 3Olpasiran
Cardiovascular Disease
Recruiting
2028-06-15
1
Phase 3Xaluritamig
Metastatic Castration-resistant Prostate Cancer
Recruiting
2030-01-07
1
Phase 3Darbepoetin alfa and Epoetin alfa
Anemia
Completed—1
Phase 2anakinra
Rheumatoid Arthritis
Terminated
2003-03past
1
Phase 2100 mg AMG 162
Osteoporosis
Completed
2007-06past
1
Phase 2Panitumumab (ABX-EGF)
Colorectal Cancer+4 more
Completed
2007-09past
1
Phase 2AMG 386 placebo
Gastrointestinal Cancer
Completed
2010-03past
1
Phase 2AMG 386
Ovarian Cancer+4 more
Completed
2011-10past
2
Phase 2Brodalumab
Crohn's Disease
Terminated
2011-10-18past
1
Phase 2CC-11050
Cutaneous Lupus Erythematosus
Completed
2013-01-01past
1
Phase 2Erenumab
Migraine
Completed
2014-09-25past
2
Phase 2Naproxen
Bone Pain in Stage I - III Breast Cancer
Completed
2015-03-18past
1
Phase 2CCX168
Immunoglobulin A Nephropathy
Completed
2015-09-13past
1
Phase 2Talimogene laherparepvec
Melanoma
Completed
2016-01-25past
1
Phase 1oprozomib
Multiple Myeloma+1 more
Terminated
2019-06-25past
2
Phase 2Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Completed
2022-12-20past
1
Phase 1Efavaleukin alfa
Rheumatoid Arthritis RA+1 more
Terminated
2023-05-22past
2
Phase 2HZN-825 BID
Diffuse Cutaneous Systemic Sclerosis+1 more
Terminated
2025-02-24past
1
Phase 2Sotorasib
Non-small Cell Lung Cancer+1 more
Active, not recruiting
2026-05-30
2
Phase 1AMG 623
Systemic Lupus Erythematosus
Completed
2007-08past
2
Phase 1MP-376 (Levofloxacin solution for Inhalation)
Cystic Fibrosis
Completed
2007-12past
1
Phase 1AMG 557
Systemic Lupus Erythematosus
Completed
2012-05past
1
Phase 1AMG 319
Cancer+13 more
Completed
2013-10past
1
Phase 1AMG 333
Migraine
Completed
2014-09past
1
Phase 1Carfilzomib
Relapsed Multiple Myeloma+2 more
Completed
2015-04past
2
Phase 1MEDI7734
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Completed
2017-10-23past
1
Phase 1VIB9600
Safety Issues
Terminated
2019-04-08past
1
Phase 1AMG 510
Healthy Participants
Completed
2020-01-26past
1
Phase 1AMG 171
Obesity
Terminated
2021-09-10past
1
Phase 1VIB1116
Dendritic Cell -Mediated Rheumatic Diseases
Completed
2023-07-03past
1
Phase 1AMG 133
Overweight or Obesity
Completed
2025-11-26past
1
N/ARomiplostim (formerly AMG 531)
Hematology+3 more
Completed
2011-07-18past
1
N/AUnnamed
Acute Lymphoblastic Leukemia
Completed
2014-03past
1
N/AUnnamed
Anaemia
Completed
2015-04past
1
N/AUnnamed
Osteonecrosis of the Jaw
Completed
2020-12-16past
1
N/AUnnamed
Medical Conditions to be Studied+2 more
Completed
2021-08-06past
1
N/Aerenumab-aooe
Migraine
Recruiting
2027-10-28
1
N/ATarlatamab
Small Cell Lung Cancer
Approved For Marketing—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.